Skip to main
PHR

Phreesia Inc (PHR) Stock Forecast & Price Target

Phreesia Inc (PHR) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 20%
Buy 40%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

Phreesia is a healthcare technology company that provides an integrated software platform designed to improve access to care, affordability of care, and patient health outcomes. The recent acquisition of AccessOne has been performing as expected, with high rates of providers giving permission for pharma ads on the platform and strong demand among large healthcare organizations. However, the company's top-line deceleration puts its "Rule of 40" objective in jeopardy, potentially impacting its valuation. As a result, analysts have raised their revenue and EBITDA estimates for FY27, but still see shares as fairly valued at current levels given uncertainties.

Bears say

Phreesia is facing several headwinds, including a decline in subscription revenue and slower provider adds due to more aggressive pricing. Furthermore, there are concerns about the company's ability to retain clients and cross-sell to larger health system clients. Additionally, Phreesia's acquisition of AccessOne has not been performing well, with shrinking revenue and net income, and there is ongoing litigation related to the 2024 outage of ConnectOnCall. These factors suggest a negative outlook for the company's future financial performance.

Phreesia Inc (PHR) has been analyzed by 15 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 40% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Phreesia Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Phreesia Inc (PHR) Forecast

Analysts have given Phreesia Inc (PHR) a Buy based on their latest research and market trends.

According to 15 analysts, Phreesia Inc (PHR) has a Buy consensus rating as of Aug 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Phreesia Inc (PHR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.